Here's a chart depicting the most current obesity drug market share. The trend is undeniable: Orexigen Therapeutics (OREX) is gaining, Arena Pharma (ARNA - Get Report) and Vivus (VVUS - Get Report) are falling. 

Source: IMS Health via J.P. Morgan.


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.